P2Y1 and P2Y12 receptors in hypoxia- and adenosine diphosphate-induced pulmonary vasoconstriction in vivo in the pig
- 205 Downloads
To investigate the role of P2Y1 and P2Y12 receptors in hypoxia- and adenosine diphosphate (ADP)-induced pulmonary vasoconstriction.
19 anaesthetized, mechanically ventilated pigs (31.3 ± 0.7 kg) were evaluated in normoxia and hypoxia, without (n = 6) or with P2Y1 receptor antagonist MRS2500 (n = 7) or P2Y12 receptor antagonist cangrelor (n = 6) treatment. 12 pigs (29.3 ± 0.4 kg) were evaluated before and during ADP infusion, without and with MRS2500 (n = 6) or cangrelor (n = 6) pre-treatment.
Hypoxia increased (p < 0.05) mean pulmonary artery pressure (MPAP) by 14.2 ± 1.1 mmHg and pulmonary vascular resistance (PVR) by 2.7 ± 0.4 WU. Without treatment MPAP and PVR remained unaltered (p = ns) for 90 min hypoxia. During hypoxia MRS2500 decreased (p < 0.013) MPAP by 4.3 ± 1.2 mmHg within 15 min. Cangrelor decreased (p < 0.036) MPAP to be 3.3 ± 0.4 and 3.6 ± 0.6 mmHg lower than hypoxia baseline after 10 and 30 min. PVR was, however, unaltered (p = ns) by MRS2500 or cangrelor during hypoxia. ADP increased (p < 0.001) MPAP and PVR to stabilize 11.1 ± 1.3 mmHg and 2.7 ± 0.3 WU higher than baseline. MRS2500 or cangrelor pre-treatment totally abolished the sustained MPAP- and PVR-increases to ADP.
ADP elicits pulmonary vasoconstriction through P2Y1 and P2Y12 receptor activation. ADP is not a mandatory modulator, but may still contribute to pulmonary vascular tone during acute hypoxia. Further investigations into the mechanisms behind ADP-induced pulmonary vasoconstriction and the role of ADP as a modulator of pulmonary vascular tone during hypoxia are warranted.
KeywordsADP Cangrelor HPV MRS2500 Pulmonary hypertension
Analysis of variance
Inspired oxygen fraction
Hypoxic pulmonary vasoconstriction
Mean aortic pressure
Mean pulmonary arterial pressure
Mean right atrial pressure
Pulmonary capillary wedge pressure
Partial pressure for oxygen
Pulmonary vascular resistance
Systemic vascular resistance
We would like to acknowledge the support of the animal technicians at the Department of Experimental Surgery and Medicine, the Panum Institute, University of Copenhagen, Copenhagen, Denmark, the staff at the Copenhagen Muscle Research Centre, Rigshospitalet, Copenhagen, Denmark, and the staff at the Department of Cardiology, Lund University and the Clinic for Heart Failure and Valvular Disease, Skåne University Hospital, Lund, Sweden. We moreover acknowledge the financial support of the Copenhagen Muscle Research Centre, Copenhagen, Denmark, the Maggie Stephens-, Crafoord-, Per Westling- and “ALF” Foundations, Lund, Sweden, and the Dr. Hartelii Scholarship Fund, Lund, Sweden. Cangrelor was provided by The Medicines Company, Parsippany, NJ, USA.
Conflict of interest
The authors declare that they have no conflict of interest.
- Hechler B, Nonne C, Roh EJ, Cattaneo M, Cazenave J-P, Lanza F, Jacobson KA, Gachet C (2006) MRS2500 [2-iodo-N6-methyl-(N)-methanocarba-2′-deoxyadenosine-3′,5′-bisphosphate], a potent, selective, and stable antagonist of the platelet P2Y1 receptor with strong antithrombotic activity in mice. J Pharmacol Exp Ther 316(2):556–563PubMedCentralPubMedCrossRefGoogle Scholar
- Kim HS, Ohno M, Xu B, Kim HO, Choi Y, Ji XD, Maddileti S, Marquez VE, Harden TK, Jacobson KA (2003) 2-substitution of adenine nucleotide analogues containing a bicycle[3.1.0]hexane ring system locked in a northern conformation: enhanced potency as P2Y1 receptor antagonists. J Med Chem 46(23):4974–4987PubMedCentralPubMedCrossRefGoogle Scholar